Pharmaceutical Drug Delivery Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI3993
Pharmaceutical Drug Delivery Market size is projected to experience significant growth from 2019 to 2025.
Global pharmaceutical drug delivery systems will positively impact industry growth in the coming years owing to the surge in innovative technologies in the field of drug delivery systems. New technologies such as DeviceVue, an asset tracking system used for sigma spectrum infusion system in hospitals and is designed to enhance clinical and hospital efficiency. Pharmaceutical drug delivery technologies further enhance bioavailability, drug absorption, and patient compliance. Thus, increasing patient compliance with innovative drug delivery technologies will boost global pharmaceutical drug delivery systems industry growth in the estimation period.
Pharmaceutical drug delivery systems market will witness considerable growth in the near future due to the increasing incidence of chronic diseases. Chronic diseases such as cancer require targeted drug delivery systems in order to provide effective anti-cancer treatment for patients. Pharmaceutical drug delivery systems selectively target or deliver the drug only to a specific site of action thus, reducing the frequency of dosages taken by the patient. Thus, rising pervasiveness of chronic diseases require personalized medicine level, so there is a need for the development of efficient pharmaceutical drug delivery systems in the future.
However, the high cost associated with treatment coupled with lack of reimbursement policies may restrain the demand for pharmaceutical drug delivery systems. Furthermore, stringent regulatory procedures may limit product approvals, thereby hampering pharmaceutical drug delivery market growth.
Targeted drug delivery systems will show momentous growth due to its various advancements in the treatment of chronic diseases such as CNS targeted drug delivery system, cancer targeted drug delivery System, cancer biomarkers, in-vitro drug release characterization models, and biomarkers in drug targeting and delivery system. Furthermore, the rise in geriatric population that is prone to various chronic diseases, increasing R&D expenditure, and emerging market economies will offer lucrative growth opportunities for these systems in the forthcoming period.
Oncology segment will hold a significant revenue size over the forecast years due to the increase in prevalence of various types of cancer such as breast cancer, lung cancer, skin cancer, and others. According to the World Health Organization (WHO), in 2018, approximately 1 in 6 deaths occur due to cancer worldwide. Additionally, targeted drug delivery systems improve the cancer treatment drastically by delivering the medicament to the targeted tumor tissue and not to the non-targeted tissue. Thus, specific delivery treatment increases the action of absorption and eradicate the tumor tissue, thereby improving the disease outcome in cancer patients. Aforementioned factors will drive the segmental growth over the forthcoming years.
Injectable segment will show momentous growth due to the growing incidence of chronic diseases, growing demand for biosimilar products and low cost of devices and manufacturing. Moreover, recent technological advancements such as reusable and disposable insulin injection pens, insulin pumps, auto-injectors pen devices, needle free devices, and smart injection devices will offer lucrative opportunities for segmental growth.
Hospitals segment will show momentous growth owing to the availability of improved and specialized technology-based pharmaceutical drug delivery systems in these facilities. Growing infrastructure to provide quick therapy transitions and favorable reimbursement policies will enhance market growth. Furthermore, increasing number of hospitalizations will drive the segmental growth during the projection timeframe.
U.S. pharmaceutical drug delivery market is estimated to foresee a lucrative growth over the forecast period due to the increasing investment in R&D sector for advanced drug delivery devices. For instance, in April 2019, Duobrii received the first U.S. FDA approval drug for the topical treatment of plaque psoriasis. Additionally, increasing prevalence of chronic diseases such as cancer, diabetes, and cardiac disorders will also drive industry growth.
Asia Pacific pharmaceutical drug delivery market is estimated to witness lucrative growth over the forecast period due to increasing incidence of chronic diseases such as asthma, cancer, tuberculosis and chronic obstructive pulmonary disease (COPD), heart diseases, and others. Moreover, the increasing geriatric population in economies such as Japan and China will drive the market growth in the estimation period.
Few of the key companies operating in the pharmaceutical drug delivery market include Johnson & Johnson Services, Inc., Novartis AG, Hoffmann-La Roche Ltd., Pfizer Inc., and Bayer AG. The industry players focus on growth strategies such as mergers and acquisitions to expand their business product portfolio. For instance, in April 2019, CURE Pharmaceutical acquired Chemistry Holdings Inc., a privately held pharmaceutical company that develops innovative delivery systems for a variety of industries. This strategic acquisition will help the company to expand the superior pharmaceutical drug delivery system product portfolio.
Pharmaceutical Drug Delivery Market by Type of Delivery system, 2014-2025 (USD Million)
- Intrauterine implants
- Prodrug implants
- Polymeric drug delivery
- Targeted drug delivery
Pharmaceutical Drug Delivery Market by Application, 2014-2025 (USD Million)
- Infectious diseases
- Central nervous system diseases
- Cardiovascular diseases
- Respiratory diseases
Pharmaceutical Drug Delivery Market by Route of Administration, 2014-2025 (USD Million)
Pharmaceutical Drug Delivery Market by End-use, 2014-2025 (USD Million)
- Homecare settings
- Ambulatory surgical centers
- Diagnostic centers
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Johnson & Johnson Services, Inc.
- Novartis AG
- Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Bayer AG
- Antares Pharma
- Becton, Dickinson and Company
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Amgen Inc.
- Bayer AG
- Boston Scientific Corporation
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.